

Applicants: Bruce D. Gaynor, Betty A. Diamond, Matthew D. Scharff,
and Philippe Valadon
Serial No.: 08/833,838
Filed: April 10, 1997
Page 3

(SEQ ID NO:2), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser; or (iv)
X1-Gly-X1-Trp-Pro-Arg (SEQ ID NO:5), wherein X1 represents Asp or Glu.

55. (amended) The method according to Claim 54 wherein said
peptide is 5-30 amino acids in length and comprises X-Gly-Trp-X-Arg-Val (SEQ ID NO:3),
wherein X represents any amino acid known in the art.

56. (amended) The method according to Claim 54 wherein said
peptide is 5-15 amino acids in length and comprises X-Gly-Trp-X-Arg-Val (SEQ ID NO:3),
wherein X represents any amino acid known in the art.

57. (amended) The method according to Claim 54 wherein said
peptide is 5-10 amino acids in length and comprises X-Gly-Trp-X-Arg-Val (SEQ ID NO:3),
wherein X represents any amino acid known in the art.

58. (amended) The method according to Claim 54 wherein said
peptide consists of X-Gly-Trp-X-Arg-Val (SEQ ID NO:3), wherein X represents any amino
acid known in the art.

59. (amended) The method according to Claim 54 wherein said
peptide is 5-30 amino acids in length and comprises X-Trp-X-Tyr-His-X (SEQ ID NO:4),
wherein X represents any amino acid known in the art.

Applicants: Bruce D. Gaynor, Betty A. Diamond, Matthew D. Scharff,
and Philippe Valadon
Serial No.: 08/833,838
Filed: April 10, 1997
Page 4

60. (amended) The method according to Claim 54 wherein said peptide is 5-15 amino acids in length and comprises X-Trp-X-Tyr-His-X (SEQ ID NO:4), wherein X represents any amino acid known in the art.

61. (amended) The method according to Claim 54 wherein said peptide is 5-10 amino acids in length and comprises X-Trp-X-Tyr-His-X (SEQ ID NO:4), wherein X represents any amino acid known in the art.

62. (amended) The method according to Claim 54 wherein said peptide consists of X-Trp-X-Tyr-His-X (SEQ ID NO:4), wherein X represents any amino acid known in the art.

C1
63. (amended) The method according to Claim 54 wherein said peptide is 5-30 amino acids in length and comprises X1-Trp-X1-Tyr-X2 (SEQ ID NO:2), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

64. (amended) The method according to Claim 54 wherein said peptide is 5-15 amino acids in length and comprises X1-Trp-X1-Tyr-X2 (SEQ ID NO:2), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

65. (amended) The method according to Claim 54 wherein said peptide is 5-10 amino acids in length and comprises X1-Trp-X1-Tyr-X2 (SEQ ID NO:2), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

Applicants: Bruce D. Gaynor, Betty A. Diamond, Matthew D. Scharff,
and Philippe Valadon
Serial No.: 08/833,838
Filed: April 10, 1997
Page 5

C2 66. (amended) The method according to Claim 54 wherein said peptide consists of X1-Trp-X1-Tyr-X2 (SEQ ID NO:2), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

71. (amended) The method according to Claim 54 wherein said peptide is 5-30 amino acids in length and comprises d-Asp-Trp-Glu-Tyr-Ser (SEQ ID NO:2).

Sub D2 C3 72. (amended) The method according to Claim 54 wherein said peptide is 5-15 amino acids in length and comprises d-Asp-Trp-Glu-Tyr-Ser (SEQ ID NO:2).

73. (amended) The method according to Claim 54 wherein said peptide is 5-10 amino acids in length and comprises d-Asp-Trp-Glu-Tyr-Ser (SEQ ID NO:2).

74. (amended) The method according to Claim 54 wherein said peptide consists of d-Asp-Trp-Glu-Tyr-Ser (SEQ ID NO:2)

C4 Please attach at the end of the application pages 1-9 of the Sequence Listing (attached hereto as Exhibit B).

REMARKS

Claims 54-74 were pending in the above-identified application. By this Amendment, applicants have amended the specification to refer to sequence identifiers,